EAElham Ahmadipour

Elham Ahmadipour

*This is an algorithmically generated author record based on publicly available information.

Elham Ahmadipour has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The association between triglyceride-glucose index and contrast-induced nephropathy; a systematic review and meta-analysis

    by Maede Safari, Akram Kadhim Kareem, Khorsid Rigi, Akbar Abbasi, Bahman Mokhtarinia, Paniz Pourpashang, Elham Ahmadipour, Batool Heydarisadegh, Halime Aali

    Introduction: The triglyceride-glucose index (TyG) is an indicator of insulin resistance, which can cause chronic dysfunction in renal performance. Accordingly, the present study aimed to examine the association between high TyG index levels and the risk of contrast-induced nephropathy (CIN) using systematic review and meta-analysis methods. Materials and Methods: Searches were conducted across several databases, including Web of Science, Cochrane Library, ProQuest, PubMed, Embase, and Google Scholar. Data was analyzed using STATA 14 software, and tests with P<0.05 were considered statistically significant. Results: High TyG index levels in total population (odds ratio [OR]: 2.24, 95% CI: 1.85, 2.71), in China (OR: 2.16, 95% CI: 1.76, 2.66), Turkey (OR: 2.77, 95% CI: 1.66, 4.6), cohort studies (OR: 2.13, 95% CI: 1.64, 2.78), case-control studies (OR: 2.59, 95% CI: 1.92, 3.51), and cross-sectional studies (OR: 2.17, 95% CI: 1.21, 3.89) increased the risk of CIN. On the other hand, the relationship between high TyG index levels among women (OR: 1.22, 95% CI: 0.84, 1.77) and CIN was insignificant. Furthermore, the association between high age (OR: 1.03, 95% CI: 1, 1.05), low-density lipoprotein (LDL) cholesterol (OR: 1.08, 95% CI: 1.03, 1.14), and eGFR (OR: 0.98, 95% CI: 0.96, 0.99) and the risk of CIN was statistically significant, but there was no significant relationship between blood hypertension (OR: 1.46, 95% CI: 0.95, 2.24), systolic blood pressure (SBP) (OR: 1.01, 95% CI: 0.99, 1.02), diastolic blood pressure (DBP) (OR: 1, 95% CI: 0.98, 1.03), diabetes mellitus (DM) (OR: 1.36, 95% CI: 0.58, 3.18), fasting blood glucose (FBG) (OR: 1.06, 95% CI: 0.97, 1.16), and hemoglobin (OR: 0.97, 95% CI: 0.94, 1.01) and the risk of CIN. Conclusion: High TyG index levels, high age, and LDL cholesterol levels increased the risk of CIN, indicating that the TyG index can be a strong predictor for the occurrence of CIN. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420250651085 )and Research Registry (UIN: reviewregistry1951) websites.

  • Open Access

    Air pollution and kidney disease; a comprehensive updated overview of recent evidence on functional and structural alterations

    by Iman Ghasemzadeh, Mohadeseh Javadi, Pourya Bagherian Kenari, Ali Emadzadeh, Meysam Ziaei Mehr, Elham Ahmadipour, Hossein Mardanparvar, Seyedeh Arefeh Javadi

    The association between air pollution and renal health has gained increasing attention in recent years, with evidence suggesting that prolonged exposure to air pollution poses significant threats to both renal function and structural integrity of kidneys, with both immediate and long-term consequences on kidney health. Studies have indicated that various air pollutants are linked to the onset and progression of chronic kidney disease (CKD) and other renal disorders. The evidence links short-term increases in pollutant concentrations to declines in glomerular filtration rates, while long-term exposure is associated with a heightened risk of CKD and structural damage to renal tissues. The mechanisms through which air pollution impacts renal health, systemic inflammation, oxidative stress, endothelial dysfunction, and direct nephrotoxicity highlight the urgent need for public health policies aimed at improving air quality and protecting kidney health. The evidence emphasizes air pollution as a critical environmental risk factor contributing to kidney diseases globally.

  • Global trends in kidney failure incidence over a 5-year period of 2019–2023; an ecological analysis of the International Society of Nephrology data

    by Mahboobeh Askarizade, Farnaz Saberian, Samaneh Zandifar, Aria Jenabi, Elham Ahmadipour, Sina Homaee, Hamid Nasri, Hossein Mardanparvar, Paniz Pourpashang

    Introduction: Kidney failure, a critical global health issue, has shown varying trends in incidence across different regions over the past five years. Objectives: This ecological analysis examines data from the International Society of Nephrology (ISN) to identify the trend pattern of kidney failure incidence between 2019 and 2023 across the world. Methods: This ecological study was conducted to evaluate kidney failure incidence across 78 countries over a five-year period (2019–2023) using data from the ISN Global Kidney Health Atlas (GKHA). Data were sourced from the ISN-GKHA website and included information for 78 countries across 10 global regions. The analysis involved extracting datasets from 2019 and 2023 to calculate changes in kidney failure incidence, identifying regional and global trends. Results: The results indicated that high-income countries exhibited varying trends in kidney failure incidence. For instance, Taiwan, Korea, and Chile experienced significant increases, whereas the Czech Republic and Panama recorded decreases. In middle-income countries, the patterns were mixed; Indonesia, Mexico, and Tunisia show marked rises, while Ecuador and El Salvador reported notable declines. Meanwhile, countries like Bahrain, Egypt, Georgia, Iran, and South Africa demonstrated stable rates, potentially reflecting steady healthcare systems or reliable data collection practices. Conclusion: The incidence of kidney failure across countries revealed diverse trends influenced by income levels and healthcare systems. High-income countries demonstrated variability, with significant increases in Taiwan, Korea, and Chile, contrasted by declines in the Czech Republic and Panama. Middle-income nations exhibited mixed patterns, as Indonesia, Mexico, and Tunisia reported rising rates, while Ecuador and El Salvador experienced declines. The stability observed in countries such as Bahrain, Egypt, Georgia, Iran, and South Africa suggests consistent healthcare infrastructure or effective data collection practices. Registration: This study has been compiled based on data from the ISN-GKHA website, and its protocol was registered on the research registry (UIN: researchregistry11142) website (https://gkha.theisn.org/).

  • Open Access

    Association between oxidative balance score and metabolic syndrome: a systematic review and meta-analysis

    by Aliasghar Tabatabaei Mohammadi, Mohammad Reza Farnia, Afsaneh Mirshekari, Sara Rashki Ghalehno, Elham Ahmadipour, Zahra Bazargani, Elham Kebriyaei, Sina Salati, Mehrangiz Ghafari

    Introduction: Most patients with metabolic syndrome (MetS) are at enhanced risk of oxidative stress. This systematic review and meta-analysis assesses the association between oxidative balance score (OBS) and MetS (MetS). Method: Cochrane, Web of Science, PubMed, ProQuest, Embase, and Google Scholar databases were searched until January 15, 2025. Data were analyzed using IBM SPSS Statistics 19.0 and STATA 14. The results with P<0.05 were considered to be statistically significant. Results: Elevated OBSs were associated with declined risks of MetS in males (OR:0.88, 95% CI: 0.83, 0.93) and females (OR: 0.81, 95% CI: 0.76, 0.86). Likewise, elevated OBSs declined the risk of MetS in South Korea (OR: 0.75, 95% CI: 0.67, 0.84) and the USA (OR: 0.63, 95% CI: 0.53, 0.74), in the cohort (OR: 0.73, 95% CI: 0.63, 0.85) and cross-sectional (OR: 0.67, 95% CI: 0.58, 0.76) studies, in 40 to 49 years old patients (OR: 0.63, 95% CI: 0.53, 0.74) and patients aged 50 to 59 (OR:0.84, 95% CI: 0.77, 0.91), in the second (OR: 0.75, 95% CI: 0.66, 0.84) and third (OR: 0.50, 95% CI: 0.34, 0.74) tertiles, in the second (OR: 0.84, 95% CI: 0.78, 0.92), third (OR: 0.68, 95% CI: 0.59, 0.79), and fourth (OR: 0.50, 95% CI: 0.41, 0.61) quartiles, and in the fifth quintile (OR: 0.78, 95% CI: 0.63, 0.97). As such, the risk of MetS declined at elevated dietary oxidative balance score (DOBS) (OR: 0.79, 95% CI: 0.62, 1) and lifestyle-based oxidative balance score (LOBS) (OR: 0.39, 95% CI: 0.21, 0.71). Conclusion: Elevated OBS, DOBS, and LOBS scores mitigate the risk of MetS. MetS risk is lower in the United States females and those in their fourth decade. Collectively, MetS is less probable to occur at elevated OBS levels. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42025643042 and Research Registry (UIN: reviewregistry1951) websites.


  • Open Access

    Treatment of IgA nephropathy; focus on reducing proteinuria by endothelin A receptor antagonists

    by Elham Ahmadipour, Hamid Nasri

    IgA nephropathy (IgAN) is the most frequent primary glomerulonephritis throughout world and a leading cause of chronic renal failure across with end-stage kidney failure. Proteinuria, as a hallmark of IgAN, is a key driver of disease progression and a strong predictor of poor renal outcome. Despite current standard therapies, including RAAS (renin-angiotensin-aldosterone system) blockade with ACEIs (angiotensin-converting enzyme inhibitors) or ARBs (angiotensin II receptor blockers), many patients continue to experience persistent proteinuria and progressive kidney function decline. This condition emphasizes the need for more effective and targeted treatment strategies. The endothelin pathway, particularly endothelin-1 signaling promotes vasoconstriction, inflammation, and fibrosis, contributing to podocyte dysfunction and renal damage. Endothelin A receptor antagonists demonstrate renoprotective properties through various mechanisms in IgAN. By selectively blocking endothelin A receptors, these agents can improve glomerular hemodynamics by reducing intraglomerular pressure, thereby alleviating the damage caused by excessive pressure and promoting an improved renal environment. This blockade leads to decreased proteinuria, as a crucial factor in the progression of the disease. Furthermore, endothelin A receptor antagonists can also mitigate inflammatory pathways that are activated in response to endothelin-1, reducing renal inflammation and subsequent fibrosis. The efficacy of endothelin A receptor antagonists in the treatment of IgAN has been substantiated by numerous clinical trials. In particular, atrasentan, a specific endothelin-A receptor antagonist, has shown significant promise in reducing proteinuria compared to placebo.


  • Open Access

    Lupus anticoagulant in patients with COVID-19: A review

    by Milad Nazari Sabet, Elham Ahmadipour, Shadi Zamansaraei

    Introduction: Coronavirus disease 2019 (COVID-19) is characterized by a pro-coagulant state that can lead to fatal thromboembolic events. A high prevalence of lupus anticoagulant has been shown in several studies that may at least partially explain the pro-coagulant profile of COVID-19. However, the relation between COVID-19 and lupus anticoagulant is arguable, and no study has clearly evaluated the concussion of lupus anticoagulant on mortality. Methods: We searched the articles that related to lupus anticoagulant and patients with COVID-19. Two authors independently reviewed the search results to select English language articles discussing lupus anticoagulant in patients with COVID-19. Results: Recent studies found conflicting results about the association between lupus anticoagulant and thromboembolic complications of COVID-19. Studies documented a high prevalence of lupus anticoagulants as well as several other studies. Patients with lupus anticoagulants were older, and their C-reactive protein, high-sensitivity troponin, and activated partial thromboplastin time (aPTT) were significantly higher than patients without lupus anticoagulants. Conclusion: Those started on therapeutic anticoagulation showed more severe and complicated involvements and a higher risk of death. According to our results, lupus anticoagulant is highly prevalent among hospitalized COVID-19 patients. Whether these antibodies promote a hypercoagulable state or they are merely a coincidence, epiphenomenon needs further evaluation.